10/5/2012

Type 2 diabetes patients who received the injection-free exenatide ITCA 650 attained significant improvements in body weight, HbA1C, fasting plasma glucose and postprandial glucose levels, with greater effects seen in those who received higher doses than those who took a lower dose. However, researchers said 40 mcg and 60 mcg doses of ITCA 650 were better tolerated compared with the 80 mcg dose. The findings were presented at the European Association for the Study of Diabetes meeting.

Related Summaries